Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors |
| |
Authors: | Jonathan Strosberg Larry Kvols |
| |
Affiliation: | Jonathan Strosberg, Larry Kvols, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States |
| |
Abstract: | Somatostatin analogs were initially developed for the control of hormonal syndromes associated with neuroendocrine tumors (NETs). In recent years, accumulating data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in patients with metastatic neuroendocrine malignancies, including carcinoid and pancreatic endocrine tumors. A phase Ⅲ, randomized, placebo-controlled trial has now demonstrated that octreotide long-acting repeatable (LAR) 30 mg can significantly prolong time to tumor progression among patients with metastatic midgut NETs regardless of functional status, chromogranin A level or age. In addition to significantly lengthening time to tumor progression in the overall study population, subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization with octreotide LAR 30 mg, supporting the early use of octreotide LAR in patients with metastatic disease. Further research efforts are underway to evaluate the use of somatostatin analogs as antiproliferative agents in other types of gastroenteropancreatic-NETs. Ongoing studies are also evaluating novel somatostatin analogs and somatostatin analogs in combination with other anti-tumor therapies. |
| |
Keywords: | Somatostatin analogues Neuroendocrine tumors Antiproliferative |
本文献已被 CNKI 维普 万方数据 等数据库收录! |
| 点击此处可从《World journal of gastroenterology : WJG》浏览原始摘要信息 |
|